Dinona
Records under this name other than patents Dinona holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,900,586 | Antibody That Binds Domain 2 of ICAM-1 and Methods of Treatment Formerly held In force · High confidence | In force | High confidence | |
| US 10,472,418 | Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,246,517 | Antibody Binding to Carbonic Anhydrase and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,220,543 | Antibody binding specifically to CD66c and use thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,269,884 | Antibody Specifically Binding to ICAM-1 and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,905,331 | Antibody binding specifically to CD40 and use thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,091,457 | Use for preventing and treating myeloid-derived suppressor cell-related diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,622,560 | Monoclonal antibody specific for CD43 epitope Formerly held Term ended Term ended May 20, 2026 · From the USPTO record | Term ended | Term ended May 20, 2026 | From the USPTO record |
| US 8,753,636 | Acute leukemia and lymphoblastic lymphoma-specific CD43 epitope and use thereof Formerly held Term ended Term ended Dec 20, 2025 · From the USPTO record | Term ended | Term ended Dec 20, 2025 | From the USPTO record |
| US 9,746,474 | Acute leukemia and lymphoblastic lymphoma-specific CD43 epitope and use thereof Formerly held Lapsed on the fee record Ended Aug 29, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 29, 2025 | From the USPTO record |